

Bundesanstalt für Arbeitsschutz und Arbeitsmedizin Federal Institute for Occupational Safety and Health

Justification Document for the Selection of a CoRAP Substance

Substance Name (public name):): 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-	
	hexamethyl-2-naphthyl)ethan-1-one	
EC Number:	216-133-4 and 244-240-6	
CAS Number:	1506-02-1 and 21145-77-7	
Authority:	DE MSCA	
Date:	22/03/2016	

Note This document has been prepared by the evaluating Member State given in the CoRAP update.

Table of Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3	Classification3.1.1Harmonised Classification in Annex VI of the CLP3.1.2Self classification3.1.3Proposal for Harmonised Classification in Annex VI of the CLP	5 5 5
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	6
4.1	Tonnage and registration status	6
4.2	Overview of uses	6
	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE TRAP SUBSTANCE	8
5.1.	Legal basis for the proposal	8
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	8
5.3	Initial grounds for concern to be clarified under Substance Evaluation	8
5.4	Preliminary indication of information that may need to be requested to clarify the concern	9
5.5	Potential follow-up and link to risk management	9

1 IDENTITY OF THE SUBSTANCE

1.1 Other identifiers of the substance


EC name (public):	1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2- naphthyl)ethan-1-one	
IUPAC name (public):	6-Acetyl-1,1,2,4,4,7-hexamethyltetraline	
Index number in Annex VI of the CLP Regulation:	-	
Molecular formula:	C ₁₈ H ₂₆ O	
Molecular weight or molecular weight range:	>258.41 g/mol	
Synonyms:	1-(5,6,7,8-Tetrahydro-3,5,5,6,8,8-hexamethyl-2- napthyl)ethan-1-one 6-Acetyl-1,1,2,4,4,7-hexamethyl-1,2,3,4- tetrahydronaphtalene 6-Acetyl-1,1,2,4,4,7-hexamethyltetraline 7-Acetyl-1,1,3,4,4,6-hexamethyl-1,2,3,4- tetrahydronaphtalene AHMT AHTN	

Table: Other Substance identifiers

Type of substance Mono-constituent Multi-constituent

UVCB

Structural formula:



2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

RMOA	Risk Management Option Analysis (RMOA)		
ц		Compliance check, Final decision	
	Evaluation	Testing proposal	
cesses	Ē	CoRAP and Substance Evaluation	
REACH Processes	Authorisa- tion	Candidate List	
REA	Auth	Annex XIV	
	Restri -ction	Annex XVII ¹	
Harmo -nised C&L	Annex VI (CLP) (see section 3.1)		
sses other J Ition	Plant Protection Products Regulation		
Processes under other EU legislation	Regulation (EC) No 1107/2009 Biocidal Product Regulation Regulation (EU) 528/2012 and amendments		
Previous egislation	Dangerous substances Directive Directive 67/548/EEC (NONS)		
Prev legisl	Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)		
EP) :holm ention)Ps ocol)			
(UNEP) Stockholm convention (POPs Protocol)	In relevant Annex		
Other process es/ EU legisla- tion	Other (provide further details below)		

Table: Completed or ongoing processes

¹ Please specify the relevant entry.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

No harmonised classification is available.

3.1.2 Self classification

• In the registration:

Acute Tox. 4 H302, Aquatic Acute 1 H400, Aquatic Chronic 1 H410 M-factor = 1

• The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Aquatic Chronic 1 H410 M-factor = 1

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Currently, no proposal for harmonized classification and labeling is available.

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site (accessed in April 2015)			
\boxtimes Full registration(s) (Art. 10)		Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)			
🖾 1 – 10 tpa	1	0 – 100 tpa	🗌 100 – 1000 tpa
🖾 1000 – 10,000 tpa	🗌 10,000 – 100,000 tpa		□ 100,000 - 1,000,000 tpa
1,000,000 - 10,000,000 tpa	□ 10,000,000 - 100,000,000 □ □		□ > 100,000,000 tpa
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential			Confidential
2 Joint Submissions.			

4.2 Overview of uses

The uses of AHTN indicate that the release of relevant amounts of the substance into the environment is probable. There are wide dispersive professional and consumer uses, and also wide dispersive uses in article service life.

Table: Uses

Part 1:

Manufacture Formulation Incu	dustrial Professional Cons e use use	sumer Service life System
------------------------------	---	---------------------------

Part 2:

	Use(s)	
Formulation	Compunding AHTN in fragrance oils. Compunding AHTN in products (generic).	
Uses at industrial sites	Industrial end-use of cleaning and maintenance products.	
Uses by professional workers	Professional end-use of cleaning and maintenance products. Professional end-use of hand cleaners.	
Consumer Uses	Consumer end-use of air care products. Consumer end-use of pest control products (biocidal product). Consumer end-use of cleaning	

² Data taken from ECHA dissemination site (accessed in May 2015)

	products. Consumer use of cosmetic products.
Article service life	Service life stage of scented articles. AC 5: Fabrics, textiles and apparel AC 6: Leather articles AC 31: Scented clothes AC 32: Scented eraser AC 35: Scented paper articles AC 36: Scented CD

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

5.1. Legal basis for the proposal

 \boxtimes Article 44(2) (refined prioritisation criteria for substance evaluation)

Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

□ Fulfils criteria as CMR/ Suspected CMR

Fulfils criteria as Sensitiser/ Suspected sensitiser

S Fulfils criteria as potential endocrine disrupter

□ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB

 \boxtimes Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)

Fulfils exposure criteria

□ Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns			
	Suspected CMR^1 $\Box C \Box M \Box R$	Potential endocrine disruptor	
Sensitiser	Suspected Sensitiser ³		
PBT/vPvB	Suspected PBT/vPvB ¹	Other (please specify below)	
Exposure/risk based concerns			
U Wide dispersive use	Consumer use	Exposure of sensitive populations	
Exposure of environment	Exposure of workers	Cumulative exposure	
High RCR	High (aggregated) tonnage	Other (please specify below)	

<u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-

classification) <u>Suspected PBT</u>: Potentially Persistent, Bioaccumulative and Toxic

ED-concern:

AHTN gives evidence for being an endocrine disruptor for the environment (estrogenic, antiestrogenic and antagonistic on Estradiol in fish as well as anti-progesteronic) from reporter gene assays and in vivo gene expression analyses in the livers of male medaka (Mori et al., 2007; Schreurs et al., 2005; Yamauchi et al., 2008). The studies cited above provide evidence on an in vitro level for possible multiple modes of endocrine activity of AHTN. Most strikingly, in vitro antiprogesteronic effects were observed down to concentrations of 0.01 µM. On an in vivo level to ou current knowledge there are no chronic fish and/or amphibian assays available (e.g. FSDT, LAGDA) to judge on adverse effects on an organismic in vivo level. We are aware of a risk assessment report (RAR) concerning PBT/vPvB compiled by the Netherlands from 2008 dealing with AHTN and concluding that there is no evidence for endocrine activity. However, since the studies by Mori et al., 2007; Schreurs et al., 2005 and Yamauchi et al., 2008 are not included in the RAR from 2008 and especially since the anti-progesteronic activity reported by Schreurs et al is not discussed within the RAR, we think that a reevaluation of AHTN concerning its potential for endocrine activity in wildlife species should be performed in detail during a substance evaluation. Additionally, owing to the registered uses of the substance which point towards a wide dispersive use, significant environmental exposure has to be assumed for AHTN.

5.4 Preliminary indication of information that may need to be requested clarify the concern

Information on toxicological properties	☐ Information on physico-chemical properties	
Information on fate and behaviour	Information on exposure	
Information on ecotoxicological properties	s 🗌 Information on uses	
Information ED potential	Other (provide further details below)	
Information ED potential Other (provide further details below) It is necessary to examine the endocrine disrupting properties of AHTN and the effects on the environment. For this reason information from a non-standard ED-relevant test might be required as there is no adequate in vivo study available to conclude for the environment on the apical effects on organisms. A fish sexual development test (OECD 234) or another test might be required to provide the required information. 5.5 Potential follow-up and link to risk management		
Harmonised C&L Restriction	Authorisation Other (provide further details) (ED-concern)	
If the initial concern is substantiated by the provided data an analysis of risk management options will be undertaken to identify the most adequate regulatory action. This analysis will include both Authorisation and Restriction.		

References:

Mori, T., Iida, M., Ishibashi, H., Kohra, S., Takao, Y., Takemasa, T., Arizono, K., 2007. Hormonal activity of polycyclic musks evaluated by reporter gene assay. Environmental sciences : an international journal of environmental physiology and toxicology 14, 195-202.

Schreurs, R.H.M.M., Sonneveld, E., Jansen, J.H.J., Seinen, W., van der Burg, B., 2005. Interaction of Polycyclic Musks and UV Filters with the Estrogen Receptor (ER), Androgen Receptor (AR), and Progesterone Receptor (PR) in Reporter Gene Bioassays. Toxicological science 83, 264-272.

Umweltprobenbank: http://www.umweltprobenbank.de/de/documents/selected_results/13761; access: 16.04.2015

Yamauchi, R., Ishibashi, H., Hirano, M., Mori, T., Kim, J.W., Arizono, K., 2008. Effects of synthetic polycyclic musks on estrogen receptor, vitellogenin, pregnane X receptor, and cytochrome P450 3A gene expression in the livers of male medaka (Oryzias latipes). Aquat Toxicol 90, 261-268.